Certolizumab Pegol is Effective for Chronic Plaque Psoriasis Regardless of Previous Exposure to Systemic Therapy: A Pooled Subanalysis of Ongoing Phase 3 Studies (CIMPASI-1, CIMPASI-2, and CIMPACT)
Document Type
Abstract
Publication Date
9-2018
DOI
10.1016/j.jaad.2018.05.301
Journal Title
Journal of the American Academy of Dermatology
Department
Dermatology
Recommended Citation
Blauvelt, A., Reich, K., Lebwohl, M., Paul, C., Leonardi, C., Thaci, D., Piguet, V., Drew, J., Burge, D., Peterson, L., Rolleri, R., Lacour, J., & Gottlieb, A. B. (2018). Certolizumab Pegol is Effective for Chronic Plaque Psoriasis Regardless of Previous Exposure to Systemic Therapy: A Pooled Subanalysis of Ongoing Phase 3 Studies (CIMPASI-1, CIMPASI-2, and CIMPACT). Journal of the American Academy of Dermatology, 79 (3 Suppl.1), AB66. https://doi.org/10.1016/j.jaad.2018.05.301
COinS
